secwatch.observer — SEC 8-K summary
======================================

Issuer:     Longeveron Inc. (LGVN)
CIK:        0001721484
Form:       8-K
Filed at:   2026-03-09T23:59:59+00:00
Accession:  0001213900-26-024839
Event type: leadership
Sentiment:  negative
Materiality: 0.40
Item codes: 3.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Longeveron director Richard Kender resigns; audit committee loses financial expert
--------------------------------------------------------------------------------

- Richard Kender resigned from Board and Audit Committee effective March 3, 2026, due to becoming Executive Chairman and Interim CEO of Seres Therapeutics.
- Board appointed Dr. Roger Hajjar to Audit Committee on March 4, but no member currently qualifies as audit committee financial expert.
- Company plans to appoint or submit for election a qualified director by next annual meeting or within 180-day cure period.
- Kender's resignation not due to any disagreement with the Company's operations, policies, or management.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1721484/000121390026024839/0001213900-26-024839-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1721484/000121390026024839/ea0280382-8k_longeveron.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-024839

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer